?? Big News at Acrobat Genomics! We are excited to announce our publication in Cell Reports Methods in Cell Press showcasing how we are advancing the gene editing toolkit using computationally guided high-throughput engineering. To summarize: ?? We used computational and structural guidance to identify engineering hotspots within a small protein that inhibits gene editing activity. ?? Then, we did a deep scan within this hotspot to identify designs that convert the inhibitory protein into a modulator that "dials back" potentially harmful off-target effects while retaining on-target activity. ?? In a single experiment, we tested >10,000 protein designs across millions of human cells, which is one of the largest scans in human cells to date. ?? We found that the final protein product (enAcr-1) is synergistic with pre-existing engineered Cas9 tools and, in theory, could be used to boost the DNA targeting specificity of other CRISPR-based applications. A huge shoutout to our dedicated (and nimble) team of scientists, advisors, and investors for making this happen! Thanks also to our participation in the NVIDIA Inception program, Illumina For Startups, and support within MBC BioLabs. By leveraging NVIDIA’s and Illumina’s computational and sequencing resources within our plug-and-play laboratory space, we’re engineering the future of genome editing. Curious about what’s next? Reach out—we have big things in the pipeline that we’d love to share. Let’s take the next leap together! Read the paper at this link: https://lnkd.in/gXYkSVsT. Stay tuned—there’s more to come! #GeneEditing #AI #HealthcareInnovation #NVIDIAInception #GeneTherapy
Acrobat Genomics
生物技术研究
San Carlos,California 808 位关注者
Accelerating safe and effective medicines to cure genetic diseases
关于我们
Acrobat Genomics is an early-stage, VC-backed biotech startup with a mission to invent impactful technologies that will lead to curative therapeutics. We come from a leading CRISPR lab at the interface of single cell genomics and gene editing at Stanford University and are innovators in leveraging DNA technologies and machine learning for high-throughput biology. We are located within the MBC BioLabs in San Carlos, CA, a well-equipped modern lab space with a rich community of companies building game-changing technologies.
- 网站
-
https://www.acrobatgenomics.com/
Acrobat Genomics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- San Carlos,California
- 类型
- 私人持股
- 创立
- 2022
地点
-
主要
930 Brittan Ave
US,California,San Carlos,94070
Acrobat Genomics员工
动态
-
Exciting Update from Acrobat Genomics: Advancing Gene Editing for Healthy Aging I'm thrilled to share that Acrobat Genomics has been awarded an SBIR grant from the National Institute on Aging (NIA) at the The National Institutes of Health! This funding is a significant step forward in our mission to develop gene editing tools that target the genetic roots of neurodegeneration to ultimately enhance lifespan. At Acrobat Genomics, we're integrating computational methods (i.e AI/ML and bioinformatics) with high-throughput biology to accelerate the discovery and development of next-generation gene editing tools that are efficient, precise, and deliverable as potential therapeutics. A heartfelt thank you to our incredible team, our dedicated advisors, and our supportive investors. Your expertise and commitment are the driving force behind our progress. We're eager to share more updates soon as we reach new milestones in our journey to transform healthcare and to improve lives. Stay tuned! Thanks to Acrobat team members Julia Marsiglia, Muneaki Nakamura, Kia Vaalavirta along with Ronjon Nag and Le Cong for their support of this proposal! #GeneEditing #AI #Longevity #Neurodegeneration #NIH #AcrobatGenomics #HealthcareInnovation #Startups #Funding
-
Welcome Kia!
I am excited to share that I have completed my Master’s in Biotechnology (PSM) at the University of San Francisco! I am extremely grateful to all my classmates, professors, teammates, coaches, and mentors for supporting me throughout my journey as an international student-athlete at the University of San Francisco. A special shoutout to our amazing faculty Cary Lai, Brian Young, Luwei Xie, MBA, MS, Moira Gunn, and Christina Tzagarakis-Foster for your dedication to the program. I want to extend my gratitude to Suomi-Amerikka Yhdistysten Liitto - SAM and the American-Scandinavian Foundation for having selected me as an ASF Fellow for the past year and allowing me to continue to follow my passions in the United States. Lastly, I am thrilled to continue working at Acrobat Genomics as a Research Associate I to develop novel gene editing therapeutics. I am very thankful to Nick Hughes and Julia Marsiglia for the opportunity to keep working with such an inspiring team and I look forward to what's coming next! ??
-
We are thrilled to announce that we’ve been selected as a spoke of the ARPA-H Investor Catalyst Hub network! ?? ?? ? We are excited to be a part of this nationwide network dedicated to accelerating groundbreaking advances in science and medicine—all in pursuit of better health outcomes for everyone. Learn more: https://lnkd.in/g4eBCSj3 #ARPAH #ARPANETH #MedTech #HealthTech #InvestorCatalystHub #HealthInnovation Looking forward to working with: Advanced Research Projects Agency for Health (ARPA-H) VentureWell ARPA-H Investor Catalyst Hub
Acrobat Genomics Selected as Member of ARPA-H Investor Catalyst Hub Spoke Network — Acrobat
acrobatgenomics.com
-
We are thrilled to announce that Acrobat Genomics has been selected as part of the California Life Sciences (CLS) FAST cohort! ?? A big thank you to Shikha Sharma and her team for this exciting opportunity.
California Life Sciences is proud to announce our Spring 2024 FAST cohort! These startups have been selected to receive 12 weeks of business mentoring from expert advisors through California Life Sciences’ advisory program, FAST California. Now in its eleventh year, FAST supports founders of early-stage disruptive and innovative life science startups. Congratulations to all participants and thank you to our program advisors & sponsors for their support. To learn more about these innovative start-ups go here: https://bit.ly/3TPIL6U Acrobat Genomics, Anviron, CDR3 Therapeutics ,Humanity Neurotech, Immoon Therapeutics, Julie Saba, Kofimi Technology, Inc., Michael Kelner, Sayenza Biosciences, Orphagen Pharmaceuticals, VIAN Therapeutics, Yuguang Yuan
-
?? Exciting News from Acrobat Genomics! ?? We're thrilled to announce our acceptance into the NVIDIA Inception Program! Their BioNeMo framework and cloud computing resources will accelerate the development of our gene editing technology. Stay tuned for more exciting news to come from this collaboration. #nvidiainception #GeneEditing #aihealthcare
-
It has been a very inspiring (and somewhat rainy) week @JPM 2024. It started with an opportunity to present our work at a fascinating AI and Longevity Science symposium hosted by R42 Group and ended with a fireside chat hosted by NVIDIA and Recursion. Jensen Huang shared his vision on how AI will fuel biological innovation. At Acrobat Genomics, we are excited to contribute to this exciting wave that promises to improve human health!
-
?? Pre-print alert ?? At Acrobat Genomics, we are ending the year on a high note while following the groundbreaking Casgevy approval! Thanks to the hard work of the team, especially Julia Marsiglia and Kia Vaalavirta in the lab, we are releasing some of our ongoing research in bioRxiv. In it, we present a generalizable approach to engineer the interaction between an anti-CRISPR protein and Cas9 in order to increase the precision of gene editing. Some highlights: 1. Protein language model identified engineering hotspots within an anti-CRISPR protein through zero-shot prediction. 2. Biology is still important! We used rational design to tune the hotspot 3. Deep mutational scanning of >10,000 proteins with simultaneous DNA repair outcome profiling in human cells identified protein variants within a single experiment, which saves time and money! 4. The lead variant reduced off-target editing by Cas9 by ~10X in validation experiments. 5. The lead variant reduced a newly discovered translocation between HBB and chromosome 5. Many thanks to our advisors and investors for their continued support. Look out for more updates from us in the new year! Link to pre-print: https://lnkd.in/dwhi3Q-5
Protein language model-guided engineering of an anti-CRISPR protein for precise genome editing in human cells
biorxiv.org